A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

Notify the Multiple Myeloma Research Foundation you are interested in this trial

NCT05552222

Age 18 +

Sex Both

Phase Phase 3

Third Opinion Trial Synopsis

In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. The study focuses on using a combination of therapies to improve patient outcomes. Here are some key details about the study:

The treatment involves a combination of drugs that target the cancer cells in unique ways.
It aims to enhance the effectiveness of existing therapies by using a multi-drug approach.
Patients will receive personalized treatment plans based on their individual health needs.
The study includes monitoring for side effects and overall health improvements throughout the treatment process.
Researchers are also looking at how this combination therapy affects the quality of life for patients.

This study is unique because it combines different treatment strategies that have not been used together before, potentially leading to better results for patients. By focusing on personalized care, the researchers hope to find a more effective way to manage the disease and improve patient outcomes.

Third Opinion AI Generated Synopsis

Trial Summary
The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexamethasone (DRd).

from ClinicalTrials.gov

Locations & Contact

Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.

Please share any additional considerations or concerns:

Example: Are you newly diagnosed? What treatments have you already been on?

Contacts: